专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

161. 发明申请

WO1998002147A2 TRANSDERMAL THERAPEUTIC SYSTEMS 审中-公开
标题翻译：透皮治疗系统
公开(公告)号：WO1998002147A2
公开(公告)日：1998-01-22
申请号：PCT/DE1997001517
申请日：1997-07-11
申请人： SCHERING AKTIENGESELLSCHAFT , LIPP, Ralph , GÜNTHER, Clemens
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： A61K09/70
CPC分类号： A61K31/569 , A61K9/7053 , A61K9/7061 , A61K31/565 , A61K31/575 , A61K2300/00
摘要： Transdermal therapeutic systems are disclosed for the controlled administration of second and third generation gestagenes, and possibly of oestrogens, at least partially dissolved in a matrix. The disclosed systems are characterised in that their matrix contains a copolymer of one or several esters or amides which contain vinyl groups and have the general formula (I), as well as an N-vinyl lactam of general formula (II). In the general formula (I), X symbolises a -COO- group, a -CONH- group or an -OCO- group; R1 stands for a hydrogen atom or an alkyl group with maximum 4 carbon atoms; and R2 stands for a hydrogen atom or an alkyl group with maximum 12 carbon atoms. In the general formula (II), n is a digit from 3 to 5.
摘要翻译：有用于第二代和第三代，这些都溶解在基质中至少部分和任选的雌激素的描述，其特征在于在的孕激素的控制递送的透皮治疗系统，他们的基质是一种或多种含乙烯基的酯或酰胺的共聚物通式（I），其中X象征-COO-基，-CONH-基或-OCO-团，R 1表示氢原子或具有最多4个碳原子的烷基，R2是氢原子，或具有最多12个的烷基表示碳原子，和通式（II）的一种N-乙烯基内酰胺，其中n为数字3-5装置是。

162. 发明申请

WO1997040032A1 CHIRAL PHENYLDIHYDROFURANONES AS PDE-IV INHIBITORS 审中-公开
标题翻译：手性PHENYLDIHYDROFURANONE AS PDE IV抑制剂
公开(公告)号：WO1997040032A1
公开(公告)日：1997-10-30
申请号：PCT/DE1997000826
申请日：1997-04-22
申请人： SCHERING AKTIENGESELLSCHAFT , LAURENT, Henry , ESPERLING, Peter , HAMP, Kurt , SCHNEIDER, Herbert , WACHTEL, Helmut
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： C07D307/58
CPC分类号： C07D307/33 , C07C45/292 , C07C45/71 , C07C49/84
摘要： Described are racemic and enantiomerically pure chiral phenyldihydrofuranones, their preparation and their use in drugs (selective inhibition of the cAMP-specific phosphodiesterase IV).
摘要翻译：外消旋和对映体纯的手性Phenyldihydrofuranone，其制备和用途在药物（cAMP特异性磷酸二酯酶IV的选择性抑制）进行说明。

163. 发明申请

WO1997032716A1 DEVICE FOR FEEDING MOULDING MASSES TO TABLET-COMPRESSING MACHINES 审中-公开
标题翻译：在动物平板机给料机新闻材料
公开(公告)号：WO1997032716A1
公开(公告)日：1997-09-12
申请号：PCT/EP1996000926
申请日：1996-03-06
申请人： SCHERING AKTIENGESELLSCHAFT , HILMANN, Jürgen
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： B30B15/30
CPC分类号： B30B15/304
摘要： A device for feeding moulding masses, in particular those which are problematic because of their fluidity, to tablet-compressing machines, has a controllable or adjustable dosing device (30) arranged in a supply channel (20) that ends in a filling shoe (10). The dosing device (30) has a motor-driven cellular shaft (35) surrounded by a housing (31, 32) and having at least four cells (36). The approximately horizontal axis of rotation of the cellular shaft (35) extends transversely to the supply channel (20). This device allows supplying the moulding mass in a controlled or adjusted manner to the filling shoe (10) during the tablet-compressing process and temporarily storing it therein without modifying its bulk density or fluidity.
摘要翻译：本发明涉及一种在压片机的装置用于供给成型化合物，特别是那些相对于它们的流动性有问题的，布置在在一个进给通道（20）在填充鞋（10）结束时，一个可控的或可调节的计量装置（30）是。计量装置（30）包括一个壳体的一个（31，32）所包围，马达驱动单元辊子（35）具有至少四个细胞（36）。电池筒（35）的旋转的大致水平对准的轴线横向于所述供给通道（20）。该设备使得能够供给控制期间压片过程中，模制组合物在不改变其堆积密度和它的流动行为或调节进料滑台（10）和中间那里。

164. 发明申请

WO1997030969A1 PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY 审中-公开
标题翻译：制药含肿瘤治疗和介入放射学全氟烷金属络合物使用
公开(公告)号：WO1997030969A1
公开(公告)日：1997-08-28
申请号：PCT/EP1997000684
申请日：1997-02-14
申请人： SCHERING AKTIENGESELLSCHAFT
发明人： SCHERING AKTIENGESELLSCHAFT , PLATZEK, Johannes , NIEDBALLA, Ulrich , RADÜCHEL, Bernd , SCHLECKER, Wolfgang , WEINMANN, Hanns-Joachim , FRENZEL, Thomas
IPC分类号： C07C229/06
CPC分类号： C07D295/26 , A61K31/28 , A61K31/555 , A61K33/24 , A61K45/06 , A61K49/06 , C07D257/02 , A61K2300/00
摘要： The invention relates to pharmaceutical agents containing perfluoroalkylated metal complexes of the general formula (I) RF-L-A and the use thereof in tumour therapy and interventional radiology, in which formula RF is a perfluorinated, straight-chain or branched carbon chain with the formula -CnF2nX, in which X is a terminal fluorine, chlorine, bromine, iodine or hydrogen atom and n represents the numbers 4-30, L is a binding group, and A is a metal complex or the salts thereof of organic and/or inorganic bases or amino acids or amino acid amides. L and A are defined in detail in the description.
摘要翻译：本发明涉及药物组合物包含通式（I），RF-LA，以及它们在肿瘤治疗和介入放射学用途，其中R f是全氟化的，直链或支链碳链与式-CnF2nX，在X的终端的全氟烷基化的金属络合物表示氟，氯，溴，碘或氢原子，n代表数字4-30，L为连接基团，并且a是金属配合物或有机和/或无机碱或氨基酸或氨基酸酰胺，L及其盐和A在本说明书中更详细地限定。

165. 发明申请

WO1997029188A1 METHOD FOR THE PRODUCTION OF rDSPA 'alpha'1 审中-公开
标题翻译：生产rDSPA alpha 1的方法
公开(公告)号：WO1997029188A1
公开(公告)日：1997-08-14
申请号：PCT/EP1997000441
申请日：1997-01-31
申请人： SCHERING AKTIENGESELLSCHAFT
发明人： SCHERING AKTIENGESELLSCHAFT , MCCAMAN, Michael , PUNGOR, Erno , SOUDERS, Carol , TAN, Mei, P.
IPC分类号： C12N09/72
CPC分类号： C12N9/6456 , A61K38/00 , C07K1/16
摘要： rDSPA alpha 1 is produced in commercial quantities and a purity adequate for clinical standards. The production methods utilize a series of chromatographic steps: cation exchange chromatography, followed by hydrophobic interaction chromatography, and ending with affinity chromatography.
摘要翻译： rDSPA alpha 1以商业数量生产，纯度足以满足临床标准。生产方法采用一系列色谱步骤：阳离子交换层析，然后进行疏水相互作用色谱，并以亲和层析结束。

166. 发明申请

WO1997028135A1 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS 审中-公开
标题翻译： 2,3-苯并二氮杂衍生物及其作为AMPA受体抑制剂
公开(公告)号：WO1997028135A1
公开(公告)日：1997-08-07
申请号：PCT/DE1997000225
申请日：1997-01-29
申请人： SCHERING AKTIENGESELLSCHAFT , LING, István , ABRAHAM, Gizella , SOLYOM, Sándor , HAMORI, Tamás , TARNAWA, István , BERZSENYI, Pál , ANDRASI, Ferenc , CSUZDI, Emese , SZÖLLOSY, Márta , SIMAY, Antal , PALLAGI, István , HORVATH, Katalin
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： C07D243/02
CPC分类号： C07D243/02
摘要： The invention concerns compounds of formula (I), in which: X designates hydrogen or halogen; Y designates -NR - or -N=; R , R and R designate hydrogen or different substituents; R designates optionally substituted C1-C6 alkyl; R designates hydrogen; or R and R together designate oxygen; R designates C1-C4 alkyl; and (a) designates a double bond or single bonds. Owing to their non-competitive inhibiting of the AMPA receptors, these compounds can be used as medicaments for treating diseases of the central nervous system.
摘要翻译：式（I）其中X是氢或卤素的化合物中，Y是-NR <3> - 或-N =，R <1>，R <2>和R <3>为氢或各种取代基，R <4>是任选取代的 C1-C6烷基，R <5>是氢或R <4>和R <5>一起是氧，R <6> C 1-4烷基和（a）表示双键或单键，由于它们的AMPA的非竞争性抑制受体作为用于中枢神经系统疾病的治疗药是有用的。

167. 发明申请

WO1997028104A2 BUFFER SYSTEMS FOR USE IN STABILIZING PHARMACEUTICAL PREPARATIONS 审中-公开
标题翻译：缓冲系统用于稳定药物制剂
公开(公告)号：WO1997028104A2
公开(公告)日：1997-08-07
申请号：PCT/DE1996002488
申请日：1996-12-20
申请人： SCHERING AKTIENGESELLSCHAFT , SACHSE, Andreas , HAUCK, Ralf-Siegbert , RÖSSLING, Georg , GÖRITZ, Detlef
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： C07B00/00
CPC分类号： A61K47/22 , A61K9/0019 , A61K9/127 , A61K47/12 , A61K47/18 , A61K47/183 , A61K47/26 , C07C59/265 , C07H5/06
摘要： The invention concerns buffer systems, consisting of a physiologically tolerable amine and a carboxylic acid, for use in the preparation of pharmaceutical agents.
摘要翻译：本申请涉及新的缓冲系统，包括生理上相容的胺和羧酸的，用于生产药物试剂的。

168. 发明申请

WO1997025923A2 OPTIMIZING DOSES OF CONTRASTING AGENT FOR IMAGING DIAGNOSTIC METHODS 审中-公开
标题翻译：优化染料转移于成像诊断过程
公开(公告)号：WO1997025923A2
公开(公告)日：1997-07-24
申请号：PCT/DE1997000116
申请日：1997-01-20
申请人： SCHERING AKTIENGESELLSCHAFT , KRAUSE, Werner
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： A61B06/00
CPC分类号： A61B6/481 , A61B6/504 , G06F19/00 , G06F19/321 , G06F19/3468
摘要： The invention concerns a device by means of which the type of contrasting agent injection mode (volume, injection speed) and a diagnostic appliance, e.g. a computer tomograph (CT), a magnetic resonance tomograph (MRT) or an ultrasound appliance (US), can be controlled such that both parts of the diagnosis - the application of the contrasting agent and the "recording parameters" of the diagnostic appliance - are optimized for the individual patient, and/or the resultant time-density curves or the pharmacokinetic parameters derived therefrom are used for differential diagnosis.
摘要翻译：本发明涉及一种装置，与造影剂注入（体积，注射流量），和一个诊断装置，例如类型计算机断层摄影（CT）或磁共振成像（MRI）或超声设备（US）可被控制，使得诊断的两个部分区域 - 造影剂应用和“曝光参数”诊断装置的 - 对个体患者进行优化和/或所述用于鉴别诊断获得的时间密度曲线和衍生的药代动力学参数可以使用。

169. 发明申请

WO1997025312A1 NEW ROLIPRAM DERIVATIVES AS cAMP-PDE IV INHIBITORS 审中-公开
标题翻译：新咯利普兰衍生物AS的cAMP-PDE IV抑制剂
公开(公告)号：WO1997025312A1
公开(公告)日：1997-07-17
申请号：PCT/DE1997000058
申请日：1997-01-10
申请人： SCHERING AKTIENGESELLSCHAFT , SCHMIECHEN, Ralph , LAURENT, Henry , ESPERLING, Peter , HAMP, Kurt , BREITKOPF, Alfred , SKÖTSCH, Carlo , SCHNEIDER, Herbert , WACHTEL, Helmut
发明人： SCHERING AKTIENGESELLSCHAFT
IPC分类号： C07D207/26
CPC分类号： C07D207/26 , C07D207/38 , C07D211/76 , C07D211/86 , C07D307/58
摘要： Described are compounds of the formula (I), their preparation and their use in drugs.
摘要翻译：有式（I），它们在药物的制备和用途的描述的化合物。

170. 发明申请

WO1997011680A2 HORMONE REPLACEMENT THERAPY METHOD AND HORMONE DISPENSER 审中-公开
标题翻译： HORMONE替代治疗方法和HORMONE分配器
公开(公告)号：WO1997011680A2
公开(公告)日：1997-04-03
申请号：PCT/EP1996004261
申请日：1996-09-30
申请人： SCHERING AKTIENGESELLSCHAFT
发明人： SCHERING AKTIENGESELLSCHAFT , ELLIESEN, Jörg , RIEDL, Jutta
IPC分类号： A61K09/06
CPC分类号： B65D83/0011 , A61K9/06 , A61K31/565 , A61K31/57 , B65D35/22 , B65D81/325 , B65D83/0005 , A61K2300/00
摘要： Varying the daily dose of either or both of the estrogen and the progestogen administered for hormone replacement therapy (HRT) is readily and inexpensively accomplished, without the necessity of the physician prescribing a new product each time the daily dose of the estrogen or progestogen is changed, by administering preferably transdermally the estrogen and progestogen contained in separate extrudable pharmaceutical compositions from a dispenser which contains means, preferably adjustable only by the attending physician or dispensing pharmacist, for varying the volume of either or both of the respective compositions which is dispensed as a single dose from the dispenser in response to a defined digital dispensing manipulation of the dispenser, thereby facilitating optimal compliance to a combination HRT with individually adjusted dosages of the estrogen and progestogen.
摘要翻译：雌激素和孕激素替代疗法（HRT）中的一种或两种雌激素和孕激素的日剂量随着雌激素或孕激素的每日剂量变化而变化，不需要医生处方新产品通过优选经皮内施用包含在来自分配器的分开的可挤出药物组合物中的雌激素和孕激素，其包含优选仅由主治医师或分配药剂师调节的用于改变分配为相应组合物的任一种或两者的体积响应于分配器的限定的数字分配操作，来自分配器的单次剂量，从而促进对组合HRT与雌激素和孕激素的单独调整剂量的最佳顺应性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式